New Pooled Analysis from Zilebesiran Program Presented at the 63rd European Renal Association (ERA) Congress

11 Jun, 2026 New Pooled Analysis from Zilebesiran Program Presented at the 63rd European Renal Association (ERA) Congress

A pooled analysis from the KARDIA Phase 2 studies demonstrated zilebesiran’s manageable safety profile as an add-on treatment for patients with hypertension receiving treatment with a background renin-angiotensin-aldosterone system (RAAS) inhibitor. The findings support continued evaluation of zilebesiran in the Phase 3 cardiovascular outcomes (CVOT) trial, ZENITH.

Wheeler, et al. “Zilebesiran as Add-on Treatment to RAAS Inhibitors for Patients with Hypertension: Data from KARDIA-2 and KARDIA-3 Phase 2 Trials”